CAS 1029712-80-8

Capmatinib

Description:

Capmatinib is a targeted therapy classified as a small molecule inhibitor, primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC) that harbor mutations in the MET gene. Its mechanism of action involves selective inhibition of the MET receptor tyrosine kinase, which plays a crucial role in tumor growth and metastasis. Capmatinib is known for its oral bioavailability and is typically administered in tablet form. The substance exhibits a favorable pharmacokinetic profile, with a relatively short half-life, necessitating multiple daily doses to maintain therapeutic levels. It is metabolized primarily by the liver, and its elimination is influenced by various cytochrome P450 enzymes. Capmatinib has been associated with specific side effects, including gastrointestinal disturbances and potential liver function alterations, which require monitoring during treatment. As a targeted therapy, it represents a significant advancement in personalized medicine, offering a treatment option for patients with MET-driven malignancies.

Formula: C₂₃H₁₇FN₆O

InChI: InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

InChI key: InChIKey=LIOLIMKSCNQPLV-UHFFFAOYSA-N

SMILES: C(C=1N2C(=NC1)N=CC(=N2)C3=CC(F)=C(C(NC)=O)C=C3)C4=CC5=C(C=C4)N=CC=C5

Synonyms:

• 2-Fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
• 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide
• Benzamide, 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-
• Inc 280
• Incb 28060
• Incb28060
• NC280 BenzaMide,2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-
• Nvp-Inc 280Nx
• Tabrecta
• Capmatinib
• 2-Fluoro-N-Methyl-4-(7-quinolin-6-ylMethyl-iMidazo[1,2-b][1,2,4] triazin-2-yl)-benzaMide
• NVP-INC280
• CAPMATINIB (INC280)
• BenzaMide INCB28060
• Capmatinib base
• CapMatinib (INCB28060)
• INCB28060,BenzaMide
• 2-fluoro-n-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide capmatinib
• NC280
• 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide Capmatinib (INCB28060)
• BenzaMide HCl
• INCB28060, INC280
• INCB028060
• INC28060(BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-)
• INCB 28060; INCB-28060; INC280
• CAPMATINIB (INCB28060);INCB-28060; INC-280
• INC 280 (INCB28060)
• INC280
• Capmatinib USP/EP/BP
• INC28060
• INC280 Capmatinib
• INCB28060(Capmatinib)

2-Fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

CAS: 1029712-80-8

Formula: C₂₃H₁₇FN₆O

Purity: 99%

Color and Shape: Solid

Molecular weight: 412.4191

Ref: IN-DA003ABZ

Capmatinib

CAS: 1029712-80-8

Capmatinib

Purity: ≥98%

Molecular weight: 412.42g/mol

Ref: 54-BUP15524

Capmatinib

CAS: 1029712-80-8

Formula: C₂₃H₁₇FN₆O

Molecular weight: 412.43

Ref: 4Z-C-436005

Capmatinib

CAS: 1029712-80-8

Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.

Formula: C₂₃H₁₇FN₆O

Purity: 99.24%

Color and Shape: Solid

Molecular weight: 412.42

Ref: TM-T1963

Capmatinib

CAS: 1029712-80-8

Selective c-Met kinase inhibitor

Formula: C₂₃H₁₇FN₆O

Purity: Min. 95 Area-%

Color and Shape: Slightly Yellow Powder

Molecular weight: 412.42 g/mol

Ref: 3D-FF40658